September 19, 2023

Cold virus may set the stage for Long COVID

At a Glance

  • Prior infection with a common cold coronavirus may predispose some people to develop Long COVID.
  • The findings identify a potential marker that could help identify people at high risk of developing Long COVID.
Senior Black man sitting on bed with his head in his hand and looking tired. The study's findings may help explain how Long COVID develops in some people. Wavebreak Media / Adobe Stock

Many infections with SARS-CoV-2, the virus that causes COVID-19, resolve within days or weeks. But a significant number of people have symptoms that linger for weeks, months, or even years. This is called postacute sequelae of COVID-19 (PASC)—commonly known as “Long COVID.” While several risk factors for PASC have been proposed, we still don’t understand what causes it or why some people get it and others don’t. To further complicate matters, PASC may have different causes in different people.

Some with PASC have changes in certain immune responses, suggesting an immune mechanism for PASC. PASC is particularly common among people with systemic autoimmune rheumatic diseases. These are chronic diseases, such as lupus, where the immune system mistakenly targets the body’s own tissues to cause inflammation. Up to 45% of those with these rheumatic diseases who are infected with SARS-CoV-2 develop PASC.

An NIH-funded research team—led by Drs. Zachary Wallace at Massachusetts General Hospital (MGH), Jeffrey Sparks at Brigham and Women’s Hospital, and Galit Alter at MGH, MIT, and Harvard—examined antibody responses in people with rheumatic diseases who’d had COVID-19. The team measured antibody responses to SARS-CoV-2 and various other pathogens and vaccines. They compared the responses of those who developed PASC with those who didn’t. Results appeared in Science Translational Medicine on September 6, 2023.

The team found that participants with PASC had much weaker antibody responses to SARS-CoV-2 than those without PASC. But those with PASC had enhanced responses to another coronavirus called OC43, an endemic virus that causes common cold-like symptoms. Moreover, the stronger the response to OC43 in people with PASC, the weaker their response to SARS-CoV-2. This suggests that antibodies against OC43 may also be reacting to SARS-CoV-2. The researchers observed these patterns in two independent groups of more than 40 patients with rheumatic diseases (about a third of whom had PASC).

The findings suggest that PASC may arise from a phenomenon known as immune imprinting. This refers to how a person’s history of previous infections can affect their immune response to new infections. In this case, when a person who was previously exposed to OC43 is infected with SARS-CoV-2, their immune system responds partly by using antibodies developed during OC43 infection that also recognize SARS-CoV-2. This “recall” response to OC43 leads to an inefficient overall response to SARS-CoV-2. Further research will be needed to determine if and how this weak immune response may lead to PASC.

“When it comes to viruses, first exposure can shape lifelong immunity,” Alter explains. “We know that, in the setting of influenza, previous exposure to a viral strain can influence a person’s immune response to subsequent strains. This concept may be at play for coronaviruses, too, and may influence risk of Long COVID, especially among individuals with rheumatic disease.”

It remains to be seen whether these findings will also apply to people without rheumatic diseases. But the results may help explain why PASC develops, in at least some cases. They also provide clues to help guide the development of novel treatments. Finally, they suggest a marker that could help identify people at high risk of developing PASC for enrollment in more targeted clinical trials.

—by Brian Doctrow, Ph.D.

Related Links

References: Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases. Herman JD, Atyeo C, Zur Y, Cook CE, Patel NJ, Vanni KM, Kowalski EN, Qian G, Srivatsan S, Shadick NA, Rao DA, Kellman B, Mann CJ, Lauffenburger D, Wallace ZS, Sparks JA, Alter G. Sci Transl Med. 2023 Sep 6;15(712):eadf6598. doi: 10.1126/scitranslmed.adf6598. Epub 2023 Sep 6. PMID: 37672567.

Funding: NIH’s National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and National Center for Advancing Translational Sciences (NCATS); Nancy Zimmerman; Mark and Lisa Schwartz; Anonymous donor; Terry and Susan Ragon; Massachusetts General Hospital; Ragon Institute of MGH, MIT, and Harvard; Massachusetts Consortium on Pathogen Readiness; Bill and Melinda Gates Foundation; Global Health Vaccine Accelerator Platform; Musk Foundation; R. Bruce and Joan M. Mickey Research Scholar Fund; Rheumatoid Research Foundation; Doris Duke Charitable Foundation.